Acute and subacute toxicity of 10B-paraboronophenylalanine.
The acute and subacute toxicities of 10B-paraboronophenylalanine (10B-BPA) were investigated in the rat, according to the Good Laboratory Practice Standard for safety studies on drugs in Japan. In the acute toxicity test of 10B-BPA, LD50 values of acidic 10B-BPA for intraperitoneal and subcutaneous injections were 640 mg/kg for male and 710 mg/kg for female rats, and more than 1,000 mg/kg for male and female rats, respectively. The LD50 values of neutral 10B-BPA for intraperitoneal and subcutaneous injections were more than 3,000 mg/kg for male and female rats. The difference in LD50 values between acidic and neutral 10B-BPA may be attributed to the acidity of material. From the subacute toxicity test, in which the rats were injected daily subcutaneously for 28 days, the following toxic effects of 10B-BPA were observed. Increase in ketone level in the urine was induced in all rats treated with 10B-BPA. High dose of 10B-BPA (1,500 mg/kg) induced increase in spleen weight and reticulocyte count, and decrease in hemoglobin count, thereby suggesting that 10B-BPA causes hemolysis. Increases in the leukocyte count and the ratio of neutrophils and lymphocytes were also observed in rats treated with a high dose of 10B-BPA. This may be attributed to local reactions at the injection site. There were no significant differences in the findings between control rats and rats treated with a low dose of 10B-BPA (300 mg/kg). Thus, low doses of neutral 10B-BPA may be available for use as a drug.
Taniyama
K
K
Department of Pharmacology, Kobe University School of Medicine, Japan.
Fujiwara
H
H
Kuno
T
T
Saito
N
N
Shuntoh
H
H
Sakaue
M
M
Tanaka
C
C
D000818:Animals; D001896:Boron Compounds / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D004354:Drug Screening Assays, Antitumor / Q000592:standards; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007554:Isotopes; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D009502:Neutrons; D010649:Phenylalanine / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity / Q000031:analogs & derivatives; D051381:Rats; D011919:Rats, Inbred Strains; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D001896:Boron Compounds; D007554:Isotopes; D010649:Phenylalanine; C033685:4-boronophenylalanine